Genix Pharmaceuticals Corporation
GENX.V
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 100.00 | 800.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 100.00 | 800.00 |
| Cost of Revenue | -- | -- | -- | 134.10K | 134.40K |
| Gross Profit | -- | -- | -- | -134.00K | -133.50K |
| SG&A Expenses | 78.60K | 84.10K | 89.70K | 112.20K | 118.60K |
| Depreciation & Amortization | 400.00 | 600.00 | 800.00 | 800.00 | 800.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.00K | 84.70K | 90.50K | 247.10K | 253.80K |
| Operating Income | -79.00K | -84.70K | -90.50K | -247.00K | -253.00K |
| Income Before Tax | -222.70K | -202.00K | -239.40K | -60.10K | -59.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.22 | -0.20 | -0.24 | -0.06 | -0.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -222.70K | -202.00K | -239.40K | -60.10K | -59.30K |
| EBIT | -79.00K | -84.70K | -90.50K | -247.00K | -253.00K |
| EBITDA | -45.90K | -68.40K | -89.70K | -246.20K | -252.20K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 242.17M | 240.17M | 238.17M | 236.90M | 236.90M |
| Average Diluted Shares Outstanding | 242.17M | 240.17M | 238.17M | 236.90M | 236.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |